In The News

ERC Advanced Grant for consortium member, Paola Picotti

The proposal titled "Exploiting the Tumor Proteome Activity Status for Future Cancer Therapies" will investigate the protein activity in diseased tissue with the goal to derive at a better understanding of the underlying cancer and suggest targeted therapies for the individual patient with the overall aim to more tightly connect quantitative proteomics and medical science.

The European Research council (ERC) just awarded the coveted ERC consolidator grant to Paola Picotti from ETH Zurich. The ERC funding awarded for 301 top scientists and scholars across Europe, as part of the Horizon 2020 research and innovation programme, is worth in total €600 million. With this support, the new grantees will have a chance to build up their teams and have far-reaching impact. Find out more

Consortium member, Paola Picotti honoured with EMBO Gold Medal

EMBO awards the  Gold Medal annually to honour the exceptional achievements of selected life scientists under the age of 40 in Europe. It stands for recognition of research excellence and the importance of young independent group leaders in creating a strong research environment. Babu and Picotti will each receive a gold medal and a cash prize of 10,000 euros.  Read more: Babu and Picotti honoured with EMBO Gold Medal.

ARTICLES & CONFERENCES

European Proteomics Infrastructure Consortium –
Providing Access

The online G.I.T. Laboratory Journal (Wiley Analytical Science, Vol 24 , March 2020, pg 32-35)  reports on how a European proteomics iniatitive, like EPIC-XS, can help further life science research both on a European level and globally.

European Proteomics Infrastructure Consortium – Providing Access (EPIC-XS) research community, representing countries spread across fourteen European member states

EPIC-XS KICKS OFF

The online Technology Networks Journal report on an EPIC Proteomics Kick Off.

EPIC-XS, funded as part of the Horizon 2020 Work programme, held its kick-off meeting in Amsterdam on April 25-26 2019.

Continue reading …..The EPIC-XS Consortium Kicks Off

The EPIC-XS Consortium Kicks Off.

EPIC-XS consortium members who attended the kick-off meeting in Amsterdam, from left to right: Javier Munoz, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain; Maarten Altelaar, Utrecht University, The Netherlands; Tiziana Bonaldi, Inistituto Europeo di Oncologia, Milan, Italy, and Kris Gevaert, Vlaams Instituut voor Biotechnologie, Ghent.

Proteomics Experts Unite For EPIC-XS

The online Technology Networks Journal interviewed Martina O’Flaherty about EPIC-XS.

Like many disciplines in systems biology, the proteomics research field is evolving at an astonishing rate. Recent advancements in the technologies available for proteomics research has leveraged a large number of research studies directed at exploring the role of proteins in biological processes.

Continue reading ……Proteomics experts unite for EPIC-XS

Utrecht University EPIC-XS consortium members (from left to right ): Richard Scheltema, Maarten Altelaar, Riccardo Zenezini Chiozzi and Franziska Vȯllmy.

EPIC-XS consortium members at the Keystone Symposia, on Molecular and Cellular Biology, Stockholm

A perfect opportunity arose at the Keystone Symposia in Stockholm, for some consortium members to catch up and discuss the

European Proteomics Initiative, EPIC-XS, before the kick off on the 25th of April.

From left to right: Bernhard Küster (Technical University Munich),

Jesper Olsen (University of Copenhagen) and Albert Heck (Utrecht University, EPIC-XS coordinator)

ERC Advanced Grant for consortium member, Bernhard Küster

The proposal titled "Exploiting the Tumor Proteome Activity Status for Future Cancer Therapies" will investigate the protein activity in diseased tissue with the goal to derive at a better understanding of the underlying cancer and suggest targeted therapies for the individual patient with the overall aim to more tightly connect quantitative proteomics and medical science.

The European Research council just awarded an ERC Advanced Grant to Bernhard Küster  and his team at the Chair for Proteomics and Bioanalytics. The proposal titled “Exploiting the Tumor Proteome Activity Status for Future Cancer Therapies” will investigate the protein activity in diseased tissue with the goal to derive at a better understanding of the underlying cancer and suggest targeted therapies for the individual patient with the overall aim to more tightly connect quantitative proteomics and medical science. Find out more… ERC Advanced Grant for Bernhard Küster

EPIC-XS Press Release

The European Union has awarded 10 million euro to a consortium of eighteen European research groups in the field of mass spectrometry based proteomics research throughout Europe. Read more